Literature DB >> 35500934

Analysis of Complement Gene Expression, Clinical Associations, and Biodistribution of Complement Proteins in the Synovium of Early Rheumatoid Arthritis Patients Reveals Unique Pathophysiologic Features.

Nirmal K Banda1, Kevin D Deane2, Elizabeth A Bemis2, Colin Strickland3,4, Jennifer Seifert2, Kimberly Jordan5, Katriona Goldman6, B Paul Morgan7, Larry W Moreland2, Myles J Lewis6, Costantino Pitzalis6, V Michael Holers2.   

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial hyperplasia and inflammation. The finding of autoantibodies in seropositive RA suggests that complement system activation might play a pathophysiologic role due to the local presence of immune complexes in the joints. Our first objective was to explore the Pathobiology of Early Arthritis Cohort (PEAC) mRNA sequencing data for correlations between clinical disease severity as measured by DAS28-ESR (disease activity score in 28 joints for erythrocyte sedimentation rate) and complement system gene expression, both in the synovium and in blood. Our second objective was to determine the biodistribution using multiplex immunohistochemical staining of specific complement activation proteins and inhibitors from subjects in the Accelerating Medicines Partnership (AMP) RA/SLE study. In the PEAC study, there were significant positive correlations between specific complement gene mRNA expression levels in the synovium and DAS28-ESR for the following complement genes: C2, FCN1, FCN3, CFB, CFP, C3AR1, C5AR1, and CR1 Additionally, there were significant negative correlations between DAS28-ESR and Colec12, C5, C6, MASP-1, CFH, and MCP In the synovium there were also significant positive correlations between DAS28-ESR and FcγR1A, FcγR1B, FcγR2A, and FcγR3A Notably, CFHR4 synovial expression was positively correlated following treatment with the DAS28-ESR at 6 mo, suggesting a role in worse therapeutic responses. The inverse correlation of C5 RNA expression in the synovium may underlie the failure of significant benefit from C5/C5aR inhibitors in clinical trials performed in patients with RA. Multiplex immunohistochemical analyses of early RA synovium reveal significant evidence of regional alterations of activation and inhibitory factors that likely promote local complement activation.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35500934      PMCID: PMC9133225          DOI: 10.4049/jimmunol.2101170

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  79 in total

Review 1.  Complement activation and inhibition: a delicate balance.

Authors:  A P Sjöberg; L A Trouw; A M Blom
Journal:  Trends Immunol       Date:  2009-01-12       Impact factor: 16.687

Review 2.  Factor H-related proteins determine complement-activating surfaces.

Authors:  Mihály Józsi; Agustin Tortajada; Barbara Uzonyi; Elena Goicoechea de Jorge; Santiago Rodríguez de Córdoba
Journal:  Trends Immunol       Date:  2015-05-13       Impact factor: 16.687

3.  Soluble Collectin-12 (CL-12) Is a Pattern Recognition Molecule Initiating Complement Activation via the Alternative Pathway.

Authors:  Ying Jie Ma; Estrid Hein; Lea Munthe-Fog; Mikkel-Ole Skjoedt; Rafael Bayarri-Olmos; Luigina Romani; Peter Garred
Journal:  J Immunol       Date:  2015-08-19       Impact factor: 5.422

4.  The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells.

Authors:  Paramita Baruah; Ingrid E Dumitriu; Giuseppe Peri; Vincenzo Russo; Alberto Mantovani; Angelo A Manfredi; Patrizia Rovere-Querini
Journal:  J Leukoc Biol       Date:  2006-04-14       Impact factor: 4.962

5.  Depressed synovial fluid levels of properdin and properdin factor B in patients with rheumatoid arthritis.

Authors:  S Ruddy; D T Fearon; K F Austen
Journal:  Arthritis Rheum       Date:  1975 Jul-Aug

6.  Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.

Authors:  N K Banda; B Levitt; A K Wood; K Takahashi; G L Stahl; V M Holers; W P Arend
Journal:  Clin Exp Immunol       Date:  2009-10-19       Impact factor: 4.330

7.  Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.

Authors:  C E Vergunst; D M Gerlag; H Dinant; L Schulz; M Vinkenoog; T J M Smeets; M E Sanders; K A Reedquist; P P Tak
Journal:  Rheumatology (Oxford)       Date:  2007-10-27       Impact factor: 7.580

Review 8.  Regulation of regulators: Role of the complement factor H-related proteins.

Authors:  Marcell Cserhalmi; Alexandra Papp; Bianca Brandus; Barbara Uzonyi; Mihály Józsi
Journal:  Semin Immunol       Date:  2019-11-19       Impact factor: 11.130

9.  C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid.

Authors:  Lars Hornum; Anker Jon Hansen; Ditte Tornehave; Marianne Scheel Fjording; Paula Colmenero; Inger Falbe Wätjen; Niels Henrik Søe Nielsen; Henning Bliddal; Else Marie Bartels
Journal:  PLoS One       Date:  2017-12-08       Impact factor: 3.240

Review 10.  The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.

Authors:  Yu Wang; Hui Zhang; You-Wen He
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.